ARMP - Armata Pharmaceuticals, Inc.

1.42
0.068   4.796%

Share volume: 4,666
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$1.35
0.07
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 35%
Dept financing 25%
Liquidity 26%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.58%
1 Month
-10.13%
3 Months
-31.85%
6 Months
-38.86%
1 Year
-45.38%
2 Year
-12.35%
Key data
Stock price
$1.42
P/E Ratio 
0.00
DAY RANGE
$1.38 - $1.42
EPS 
-$0.52
52 WEEK RANGE
$0.90 - $3.45
52 WEEK CHANGE
-$45.38
MARKET CAP 
66.939 M
YIELD 
N/A
SHARES OUTSTANDING 
36.183 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
0.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,067
AVERAGE 30 VOLUME 
$24,276
Company detail
CEO: Brian C. Varnum
Region: US
Website: armatapharma.com
Employees: 70
IPO year: 2006
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Armata Pharmaceuticals, Inc. focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PS03 for pneumonia.

Recent news
loading